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Background: The use of gold fiducial markers (FM) for prostate image-guided radiotherapy (IGRT) is standard
practice. Published literature suggests low rates of serious infection following this procedure of 0-1.3%, but this may
be an underestimate. We aim to report on the infection incidence and severity associated with the use of transrectally
implanted intraprostatic gold FM.
Methods: Three hundred and fifty-nine patients who underwent transrectal FM insertion between January 2012 and
December 2013 were assessed retrospectively via a self-reported questionnaire. All had standard oral fluoroquinolone
antibiotic prophylaxis. The patients were asked about infective symptoms and the treatment received including
antibiotics and/or related hospital admissions. Potential infective events were confirmed through medical records.
Results: 285 patients (79.4%) completed the questionnaire. 77 (27.0%) patients experienced increased urinary
frequency and dysuria, and 33 patients (11.6%) reported episodes of chills and fevers after the procedure. 22 patients
(7.7%) reported receiving antibiotics for urinary infection and eight patients (2.8%) reported hospital admission for
urosepsis related to the procedure.
Conclusion: The overall rate of symptomatic infection with FM implantation in this study is 7.7%, with one third
requiring hospital admission. This exceeds the reported rates in other FM implantation series, but is in keeping with the
larger prostate biopsy literature. Given the higher than expected complication rate, a risk-adaptive approach may be
helpful. Where higher accuracy is important such as stereotactic prostate radiotherapy, the benefits of FM may still
outweigh the risks. For others, a non-invasive approach for prostate IGRT such as cone-beam CT could be considered.
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Transrectal ultrasound guidedBackground
Daily image guidance is a crucial component in the
delivery of dose escalated external beam radiotherapy
for prostate cancer. Image guided radiotherapy (IGRT)
using gold fiducial markers is standard practice in many
centres. Despite their adoption into routine practice, there
is a lack of prospective evidence on the safety profile of
the implantation of the fiducial markers. Most of the stud-
ies examining the complications of fiducial markers are* Correspondence: Jarad.Martin@calvarymater.org.au
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unless otherwise stated.done through a questionnaire, with the information col-
lected retrospectively. These studies have reported low
rates of infective complications with this procedure [1-4].
However there is a high degree of bias associated with sur-
vey studies. The results are dependent on a multitude of
factors including the participant response rates, recall bias,
the questions being asked and the time frame in which
they are presented to the patient.
There is a large and often prospectively collated litera-
ture relating to the septic complications associated with
transrectal prostate biopsies and the potential risk fac-
tors [5-10]. Given the similarity between this procedure
and the fiducial marker implantation with both beingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ance, it is likely that we can draw some inferences from
the results of the more mature prostate biopsies dataset.
These suggest a rate of urosepsis of approximately 3%
and an increasing incidence of multidrug resistant in-
fections [7]. This has been used to promote alternative
approaches such as transperineal biopsy.
Apart from the potential complications related to the
procedure, the fiducial markers do incur some financial
cost. With non-invasive methods such as cone beam CT
(CBCT) and 3D ultrasound of the prostate emerging as
alternative tools for IGRT it is important to assess the
safety of using transrectally implanted fiducial markers.
Therefore the aim of our study was to evaluate the rate
of infection from transrectal fiducial marker implantation
for prostate IGRT whilst also minimizing the biases which
can affect studies of this nature.
Methods
All patients at our centre who underwent gold seed
fiducial marker implantation for prostate IGRT between
January 2012 to December 2013 were identified through
a local prospectively maintained database. The patients
had the procedure done by their local urologists. All
patients were prescribed prophylactic fluoroquinolone
antibiotics peri-procedure, and rectal enemas were not
always used. Under local anaesthetic, three gold markers
of 1.0x3.0 mm each were implanted into the prostate
base, apex and contralateral midzone with TRUS guid-
ance. Our primary endpoint was the rate of urosepsis
requiring hospital admission, with a secondary endpoint
as the rate of urinary tract infection. This study received
approval from a local human research ethics commit-
tee, the Hunter New England Human Research Ethics
Committee (HREC Reference no: 14/02/19/5/09).
Questionnaire outline
Questionnaires were sent by post in mid-March 2014.
This was followed-up with a phone call reminder if a
reply had not been received at 3 weeks. The question-
naire was 1-page long consisting of 5 questions (Additional
file 1) directed at infective symptoms and any related
treatment received including antibiotics and/or hos-
pital admissions following the procedure. Each question
required a “Yes” or “No” answer, mirroring the approach
of one of the largest previous reports [1]. There was also
space for free text comments, and many of the respon-
dents took up this option. All responses were collected
and entered into a database. For those that answered yes
to receiving antibiotic and/or hospital admissions, we
corroborated the information with their medical records
and also with their general practitioners where required.
A consensus panel then reviewed the medical information
of these patients, and where it was clear that the hospitaladmission was not related to the fiducial marker pro-
cedure, the patient was excluded from the analysis.
Descriptive statistics were prepared to summarize the
data using Excel (Microsoft, Seattle).
Results
A total of 359 patients were identified from our database
and questionnaires were sent out to all of these patients’
last recorded address. We received 297 responses (82.7%),
of which 12 declined participation. The final reply was
received approximately 6 weeks after mail out. Therefore
285 (79.4%) completed questionnaires were returned.
Seventy-seven (27.0%) men reported experiencing symp-
toms of increased urinary frequency or dysuria and 33
(11.6%) men experienced episodes of chills and fever after
the procedure.
Twenty-two (7.7%) men answered yes when asked if
they were treated for a urinary infection with antibiotics
after the procedure. For 16 of the 22 patients we were
able verify this through their medical records and there-
fore at the minimum, the rate of infectious complication
requiring antibiotic treatment in our study is 5.6%.
Eight (2.8%) patients reported a hospital admission for
infective complications related to the fiducial implant-
ation procedure. We were able to obtain medical records
of the hospital admission for 5 of the 8 patients. Therefore
the minimum rate of hospital admission for infective com-
plications in our study is 1.8%. All 5 patients presented
within 5 days of the procedure and one patient required 2
hospital admissions for persistent infection. One of the 8
patients had urosepsis after his initial TRUS biopsy, but
we were not able to verify if he had a hospital admission
following his fiducial marker procedure. Twelve (4.2%)
patients reported recurrent urinary infections requiring
antibiotics. Three of the twelve patients developed chronic
prostatitis at 7 to 12 months after completion of their
radiotherapy requiring prolonged courses of antibiotics.
E.Coli was the most common organism grown in those
with a positive urine culture, although we were not able
to obtain information on the sensitivities to fluoroquino-
lones for all of them. Other organisms isolated include
enterococcus and proteus mirabilis.
Discussion
Although fiducial markers have been widely accepted as
standard for prostate IGRT, there is a lack of quality
evidence relating to their safety. Studies evaluating the
safety of the implantation of the fiducial markers are all
single arm case series, with significant heterogeneity
across the studies (Table 1) [1-4]. Several factors may
explain the higher rate of hospital admissions reported
in our study (1.8-2.8%) compared to the published litera-
ture of between 0 to 1.3%. Similarly, the rate of urinary
infections requiring antibiotic therapy in our series at
Table 1 Studies assessing complication rates from fiducial marker implantation for prostate image guided
radiotherapy
Study Patient numbers Infective complications
Gill et al. [1] 234 3 patients (1.3%) required admission for sepsis
1 patient (0.4%) had Grade 4 septicaemia.
Langenhuijsen et al. [2] 209 4 patients (1.9%) with fever received additional antibiotics.
There were no hospital admissions.
Igdem et al. [3] 135 3 patients (2.2%) developed symptomatic urinary infection
with fever and received antibiotics.
There were no hospital admissions.
1 (0.7%) patient developed asymptomatic bacteriuria
resistant to antibiotic therapy.
Moman et al. [4] 402 had transrectal FM implantation 2 (0.5%) developed urosepsis (Grade 3 toxicity)
512 had transperineal FM implantation No grade 3 or 4 toxicity.
Loh et al. 285 22 patients (7.7%) received antibiotic treatment for a
urinary infection
8 patients (2.8%) required hospital admission for urosepsis.
TRUS biopsy series
Wagenlehner et al. [10] 521 5.2% had symptomatic urinary tract infection
3.1% required hospital admissions for infectious complications
FM = fiducial marker.
TRUS = Transrectal ultrasound guided.
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literature (1.9-2.2%). These studies all evaluated the
toxicities and complications through the use of a ques-
tionnaire. This relies heavily on the patients’ accurate
recollection of symptoms and events. The accuracy
decreases as the recall period increases. This can lead to
over or under-reporting. In our study, we chose to
include patients who underwent this procedure within
the last 2 years to minimise the possibility of recall bias.
Most of the published studies also asked about a broad
range of symptoms and toxicities. Different scales and
scoring systems were employed in the studies. In one
study, the questionnaire was up to 10 pages long. This
increases the non-response rate and can further com-
pound the recall bias. We chose to limit our questionnaire
to a single page, directed only to the infective complica-
tions. We were also able to validate the patient reported
infectious complications and the treatment received from
their medical records for the majority of patients in our
study. For these reasons, it is possible previous series have
underestimated the true incidence of infective complica-
tions associated with TRUS guided gold fiducial insertion.
Nonetheless, our study being retrospective is likely to still
suffer from similar limitations of other studies of this
nature (Table 1), with the possibility of under or overesti-
mating the complications.
There is more significant data on infectious com-
plications available in the transrectal prostate biopsy
setting. The rate of symptomatic and febrile urinary infec-
tions following transrectal prostate biopsy in large multi-institutional studies is approximately 4%, leading to hos-
pital admission in up to 3.1% of patients [7]. Although
local factors in gold seed implantation may have had an
impact on the higher infection rates we report compared
to other similar series, we note that our results are com-
parable to this transrectal biopsy data. Potential risk fac-
tors for post-biopsy infections have been identified in a
number of studies [6,8-10]. They include a high comorbid-
ity index, exposure to antibiotics within 6 months of bi-
opsy, hospital employment and recent international travel.
The presence of fluoroquinolone resistant organisms in
the faecal reservoir is a significant risk factor for post
biopsy infection [5,11,12]. Fluoroquinolone resistant bac-
teria have been detected in about 50-90% of cases with
post-TRUS biopsy infections, with emerging reports of
multidrug resistance. Currently the American Urological
Association best practice guidelines still recommend
fluoroquinolones or 1st-3rd generation cephalosporins as
antimicrobials of choice for prophylaxis. The guidelines
call for the use of an alternative anti-microbial in patients
with risk factors for infectious complications following
prostate biopsy. However, the regular use of broad-
spectrum antibiotics is not the ideal solution, as this will
possibly lead to even more resistance. The use of rectal
enemas before biopsy is under investigation, although
studies have so far not shown significantly reduced infec-
tion rates [13,14]. Pre-procedural rectal swabs to guide
prophylactic antibiotic therapy have shown promising
early results [15]. Transperineal prostate biopsy is also
being explored as a method to avoid inoculation of rectal
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sepsis with this approach, although a general anaesthetic
is often required [16]. It would seem prudent to incorpor-
ate some of these observations into the evolving under-
standing of fiducial marker placement.
There is a paucity of evidence and guidelines to iden-
tify individuals at risk and the prevention of infectious
complications following fiducial marker implantation.
Given the similarity of the two procedures, current strat-
egies have been adopted from the transrectal prostate
biopsy setting. Evidence shows that in men with prostate
cancer on active surveillance, serial repeat prostate biop-
sies are associated with a significant risk of infectious
complications [17]. For every previous biopsy the odds
of an infection increased 1.3 times [17]. There is no data
currently to show the same with fiducial marker im-
plantation following an initial prostate biopsy, but given
the similarity of the procedures, the prostate biopsy data
may also hold true in this setting. It is also not known if
the acquired infections post fiducial marker implantation
are more difficult to treat and harder to eradicate, as
unlike the post biopsy setting, the fiducial markers could
potentially serve as an enduring nidus of infection within
the prostate. One patient in our study who grew a fluoro-
quinolone resistant E.Coli required 2 hospital admissions
and long-term antibiotics for persistent infection. He
eventually required a trans-urethral resection of necrotic
prostate tissue, which is likely to have been a consequence
of his chronic infections rather than solely due to his
radiotherapy. Transperineal fiducial marker implantation
may lead to less infective complications although there is
still a risk of bleeding and pain.
Chronic prostatitis following fiducial marker implant-
ation is not easily recognisable in a clinical setting. It is a
diagnosis of exclusion, with sterile pyuria often seen in
these patients. The prolonged symptoms can impact on
the patient’s quality of life. There is scarce literature on
chronic prostatitis in this setting, likely reflecting the
under-recognition of the condition in clinical practice
and the difficulties in establishing a definitive diagnosis.
There are costs to both the health provider and to the
patients associated with this procedure. In Australia, the
minimum cost for fiducial marker implantation is just
over three hundred dollars per patient. This is excluding
the cost of the fiducial markers themselves which is
approximately one hundred and seventy dollars. The
cost also increases if the patient requires general anaes-
thetic. For the patient, the procedure requires an extra
appointment and if pre procedural infection screening
becomes routine, this will add to the number of visits. In
some cases co-ordination of the temporary cessation of
their anti-coagulation therapy is also required. One patient
in our study suffered a stroke as a consequence of subther-
apeutic warfarin levels following recommencement afterhis procedure. Although this event is uncommon, the con-
sequences for the patient when it occurs can be disastrous.
For patients who had developed a complication following
their prostate biopsy, this exposes them again to another
potential risk of complication.
The superiority of fiducial markers versus bony land-
mark based IGRT in prostate motion management is
widely accepted [18]. The use of daily fiducial marker
based IGRT is also associated with lower rates of patient
reported rectal toxicity compared to a cohort managed
with bony matching [19]. Non-invasive methods to lo-
calize the prostate gland such as 3D ultrasound [20] and
CBCT [21] with soft tissue matching have been assessed
as alternate tools for image guidance. A study comparing
soft tissue matching using CBCT versus orthogonal mega-
voltage image matching with fiducial markers showed that
in less than 5% of fractions a disagreement of >5mm was
observed. The authors hypothesized that the most ex-
treme differences in the shifts were likely due to higher
interobserver variability in locating the prostate on CBCT
images [21]. A second series also demonstrated higher
interobserver variability with CBCT soft tissue matching
compared with fiducial markers, and recommended that
this should be taken into consideration in the margin gen-
eration [22]. Nonetheless, intraprostatic fiducials do allow
greater accuracy of IGRT compared with soft-tissue based
guidance with CBCT or ultrasound. As a consequence of
this, one possibility may be to use fiducial markers mainly
where higher accuracy is important such as stereotactic
prostate radiotherapy, and CBCT in situations such as
history of urosepsis following biopsy or anticoagulation.
Such risk adaption of the method of IGRT would poten-
tially reflect the wider movement towards tailored treat-
ments in oncology.Conclusion
Fiducial marker implantation for prostate IGRT is asso-
ciated with a small percentage of patients experiencing
moderate to severe complications requiring further med-
ical interventions. However, the methods used to assess
for toxicities are insufficient to adequately capture com-
plications such as chronic prostatitis. Alternative non-
invasive methods for image guidance such as CBCT and
ultrasound might be considered for conventionally frac-
tionated prostate radiotherapy.Additional file
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